Back to news

NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR Symposium

Globe Newswire•20/11/2026•08:00 ET
0

Key Highlights

  • ➤Combination reduced multiple myeloma cell viability to 3% and 26% across models
  • ➤NUC-7738 plus carfilzomib exceeded expected activity in two of three models
  • ➤Proteasome activity fell to 25% with combination versus 52% with carfilzomib alone
  • ➤Carfilzomib ranked first among 70 partner drugs in combination screening
  • ➤NuCana expects cash resources to fund planned operations into 2029

Expert Statements

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“These findings add an important dimension to our understanding of NUC-7738’s mode of action”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“What is particularly encouraging is that the changes in proteasome function were accompanied by greater-than-expected anti-cancer activity in these preclinical models.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We believe these data strengthen the rationale for further evaluation of NUC-7738 in combination with proteasome inhibitors and across additional tumor types.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“Our priority is to define the optimal clinical development path for NUC-7738 in melanoma, informed by the forthcoming Phase 2 results and the latest translational data.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“We are also continuing our dialogue with the FDA regarding a potential registrational strategy.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“In parallel, we believe these new preclinical findings strengthen the scientific rationale for broadening the development of NUC-7738 beyond PD-1 inhibitor-resistant melanoma, through additional indications and combination strategies.”

Hugh S. Griffith, Founder and Chief Executive Officer of NuCana

“With cash resources anticipated to fund our planned operations into 2029, we are focused on advancing these priorities and selecting the most promising opportunities for further development.”

NUC-7738 Increased Proteasome Inhibition When Combined with Carfilzomib

Data Presented Identify an Additional Potential Mode of Action for NUC-7738 and Support Evaluation of Additional Indications and Combination Strategies

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in